Provided by Tiger Trade Technology Pte. Ltd.

SIMCERE PHARMA

11.460
-0.390-3.29%
Volume:2.43M
Turnover:27.79M
Market Cap:29.43B
PE:21.22
High:11.800
Open:11.800
Low:11.210
Close:11.850
52wk High:14.081
52wk Low:9.070
Shares:2.57B
HK Float Shares:2.57B
Volume Ratio:0.66
T/O Rate:0.09%
Dividend:0.21
Dividend Rate:1.84%
EPS(LYR):0.540
ROE:18.77%
ROA:7.78%
PB:2.67
PE(LYR):21.22
PS:2.88

Loading ...

Simcere Pharma repurchases 1.64 million shares; cumulative buy-backs rise to 24.13 million

Bulletin Express
·
May 19

SIMCERE PHARMA Spends HK$17.99 Million on Share Buyback

Stock News
·
May 19

SIMCERE PHARMA Executes Share Repurchase on May 18

Stock News
·
May 18

Simcere files HKEX return disclosing share repurchase at HKD 11.19 each

Reuters
·
May 18

SIMCERE PHARMA Executes Share Buyback on May 14

Stock News
·
May 15

SIMCERE PHARMA (02096) Spends HK$12.30 Million on Share Buyback

Stock News
·
May 13

Simcere files HKEX next-day return, discloses share repurchase at HKD 11.57 each

Reuters
·
May 13

Simcere Pharmaceutical Group's (HKG:2096) Solid Profits Have Weak Fundamentals

Simply Wall St.
·
May 08

Simcere Pharma Keeps Share Capital Unchanged in April 2026, Public Float Remains Compliant

Bulletin Express
·
May 06

Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug

MT Newswires Live
·
May 06

BRIEF-Simcere Pharmaceutical Receives NMPA China Clinical Trial Approval For SIM0613

Reuters
·
May 06

Simcere Pharma receives NMPA approval to begin clinical trial of LRRC15 ADC SIM0613; partnership with Ipsen worth up to US$1.06 billion progresses

Bulletin Express
·
May 06

SIMCERE PHARMA's ADC Candidate SIM0613 Receives Chinese Regulatory Nod for Clinical Trials

Stock News
·
May 06

Simcere Pharmaceutical - Receives China Clinical Trial Approval From Nmpa for Sim0613 in Advanced Solid Tumors

THOMSON REUTERS
·
May 06

Simcere Pharma buys back 1.38 million shares on 5 May; cumulative 2026 repurchases reach 15.05 million

Bulletin Express
·
May 05

Simcere Pharma Adds 847,000-Share Buyback; Cumulative Repurchases Reach 13.67 Million

Bulletin Express
·
May 04

SIMCERE PHARMA Spends HK$10 Million on Share Buyback

Stock News
·
May 04

Simcere files HKEX next-day disclosure return, reports share buyback at HKD 11.91

Reuters
·
May 04

SIMCERE PHARMA's New Drug Application for Ledokibai Monoclonal Antibody Accepted by Regulators

Stock News
·
Apr 30

Simcere says China regulator accepts NDA for atopic dermatitis drug rademikibart

Reuters
·
Apr 30